

Attorney Docket No.: 5776.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hansen et al.

Application No.: 09/872,127

Group Art Unit: 1614

Filed: June 1, 2001

Examiner: Jerome D. Goldberg

Confirmation No: 1919

For: Use of N-Substituted Azaheterocyclic Compounds for the Manufacture of a
Pharmaceutical Composition for the Treatment of Indications Related to
Angiogenesis

RESPONSE TO ELECTION REQUIREMENT

Commissioner for Patents
Washington, DC 20231

Sir:

This paper is being timely filed in response to the Office Action, Paper Number 7, mailed September 18, 2002, having a shortened statutory period for reply set to expire October 18, 2002, which made an election of species requirement for purposes of examination only. Applicants were requested to elect a specific compound which would define the X and Y groups as well as the p or q groups.

In response to this requirement, Applicants hereby elect, with traverse, for examination purposes only, the twentieth species in the list of compounds recited in claim number 5:

(R)-1-(3-(6,7-dihydro-5H-dibenzo[b,g]azocin-12yl)-1-propyl)-3-piperidinecarboxylic acid.

Claims 1, 2, 3, 4, 5, and 34 read on the elected species.




The basis for traverse is that there would not be a serious burden on the examiner if election was not required. Applicants hereby reserve the right to file continuing applications directed to the nonelected subject matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Applicants believe no fees are due regarding this response, however if it is determined a fee is required to permit timely filing of this response, please charge the required fee or credit any overpayments to Deposit Account No. 14-1447, in the name of Novo Nordisk of North America, Inc..

Respectfully submitted,




Date: October 18, 2002

Rosemarie R. Wilk-Orescan
Reg. No. 45,220
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5969



23650

PATENT TRADEMARK OFFICE



Attorney Docket No.: 5776.204-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1614
RECEIVED
PATENT

OCT 25 2002

TECHNICAL CENTER 1600/2900

In re Application of: Hansen et al.

Serial No.: 09/872,127

Group Art Unit: 1614

Filed: June 1, 2001

Examiner: Jerome D. Goldberg

Confirmation No: 1919

For: Use of N-Substituted Azaheterocyclic Compounds for the Manufacture of a
Pharmaceutical Composition for the Treatment of Indications Related to Angiogenesis

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Response to Restriction Requirement

is being deposited with the United States Postal Service as first class mail in an envelope
addressed to:

Commissioner for Patents
Washington, DC 20231

on October 18, 2002.

Dolly Kapadia
(name of person mailing paper)

Dolly Kapadia
(signature of person mailing paper)